ClinicalTrials.gg
RecruitingNCT06400992SKY-MARVELUpdated Apr 3, 2026

Investigation of Sky Automatic Technologies in Pediatrics

An interventional study of Cochlear implant processor Sky CITM M90 (CI-5295) and Hearing Aid, including sound processor Phonak: Sky Link M90 in Hearing Loss, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
6 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hearing Loss by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 7 under way, none of them phase 3. Hearing Loss · Assistance Publique - Hôpitaux de Paris.

Started
2024
with 1 other
No phase
3 of 13
2 open now
Registered
10th of 13
by date

Among the 13 studies in Hearing Loss by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2024, is one of 3 with no phase, and was the 10th registered.

Hearing Loss

797 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.

Browse Hearing Loss studies →

Open to participants now

7 of the 13 studies in Hearing Loss by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.

This study: 6 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hearing Loss by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The hypothesis of this research is that the AS Target setting provides the best estimate of the settings required to optimize listening in noise. As such, it is expected that speech in noise performance will be best in the AS Target condition, followed by the AS Clinic condition, and the Omni condition will be the least favourable for speech in noise performance.

Read the detailed description

The ability to hear speech in noise is particularly important for children, as they are often in complex listening situations like classrooms or playgrounds. In children with hearing loss, the ability to understand speech in noise is further degraded not only by decreased audibility of speech sounds, but also additionally by the distortion spectral and temporal processing cues, and reduced binaural processing abilities. Cochlear implant manufacturers have introduced a number of technologies designed to improve speech recognition in background noise. Sound processing algorithms use a variety of strategies to facilitate listening in noise, and research has shown that these advances do lead to improved performance.

AutoSense Sky OS 3.0 (AutoSense Sky OS, AS) is an automatic auditory scene classification system specifically designed for children's typical listening situations, like classrooms and playgrounds. This technology is available in the new Sky CI M90 (Sky CI), which is the latest generation of sound processor (SP) from Advanced Bionics, designed for children.

This algorithm is also available in the Sky Link M90 hearing aid (Sky Link). This means that bimodal patients, using one Sky Link and one Sky CI can benefit from AutoSense Sky OS in addition to children with two Sky CI. The combination of the two hearing devices (HD) tested in this research, whether it be two Sky CI or one Sky CI and one Sky Link, will be referred to as the Sky Hearing System (Sky HS).

As usual in standard care, children with Sky HS can have their hearing system programmed in three ways (at the discretion of the clinician):

  1. Omnidirectional mode, in which the AutoSense Sky OS is deactivated and no modifications are made by the clinician (no sound treatment)
  2. AS Target, in which the AutoSense Sky OS is active and programmed with the parameters suggested by the programming software (Target) and no modifications are made by the clinician
  3. AS clinic, in which the AutoSense Sky OS is active, and settings have been modified by the clinician (mixed setting).

The goal of this research is to compare speech in noise perception in each of those three possible programming conditions used in the standard care. The hypothesis of this research is that the AS Target setting provides the best estimate of the settings required to optimize listening in noise. As such, it is expected that speech in noise performance will be best in the AS Target condition.

03

Conditions studied

  • Hearing Loss

Browse trials for

Keywords

  • Hearing Loss
  • cochlear implant
  • hearing aid
  • hearing device
  • hearing system
  • Simplified French Matrix Test
  • Noise block
  • background noise
  • target cochlear implant
  • pediatric cochlear implant processor
04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between 6 and 16 years of age at the time of inclusion
  • Use spoken French as their primary mode of communication
  • Ability to perform the Simplified French Matrix test in Noise
  • Bimodal group: use the Sky CI processor or be eligible for a Sky CI processor upgrade on one side and use a contralateral hearing aid
  • Bilaterally implanted group: use two Sky CI processors or be eligible for an upgrade to two Sky CI processors
  • Obtain signed consent from legal guardian(s)
  • Be enrolled in a health insurance plan or eligible for coverage

Exclusion criteria

Exclusion Criteria:

  • Severe neurological pathology identified prior to inclusion identified by MRI + /- neuro-pediatric workup
  • Severe cognitive, psychiatric, or developmental disabilities identified prior to inclusion
  • Family does not understand French
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Bilaterally implanted patients

    patient with two cochlear implant in each ear

    Device: Cochlear implant processor Sky CITM M90 (CI-5295) · Device: Hearing Aid, including sound processor Phonak: Sky Link M90 · Diagnostic Test: French simplified matrix test (FraSimat) · Behavioral: Audiologist Fitting Questionnaire · Behavioral: Patient Satisfaction Questionnaire · Behavioral: AutoSens Feedback Discussion Form

  • Experimental
    Bimodal patients

    patient with cochlear implant in one ear and fitted with hearing aid audio in the other ear

    Device: Hearing Aid, including sound processor Phonak: Sky Link M90 · Diagnostic Test: French simplified matrix test (FraSimat) · Behavioral: Audiologist Fitting Questionnaire · Behavioral: Patient Satisfaction Questionnaire · Behavioral: AutoSens Feedback Discussion Form

Interventions

  • DeviceCochlear implant processor Sky CITM M90 (CI-5295)

    The Sky CI available to included patients (no procedures added) offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion: 1. Omnidirectional mode : no sound treatment 2. AS Target : Autosense is active and no modifications are made by clinician 3. AS Clinique : Autosense is active and modified by the clinician

  • DeviceHearing Aid, including sound processor Phonak: Sky Link M90

    The device is fitting and programmed for home especially for the purpose research at inclusion. The Clinical map parameters will be verified according to clinical routine. The Sky Link offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion: 1. Omnidirectional mode : no sound treatment 2. AS Target : Autosense is active and no modifications are made by clinician 3. AS Clinique : Autosense is active and modified by the clinician

  • Diagnostic testFrench simplified matrix test (FraSimat)

    The FraSimat speech in noise test will be tested, 6 months before inclusion in the three different fitting configurations: omni, AS clinic, AS Target. The speech will be presented from the front, noise from 180°. Noise will be presented at a fixed level of 65 dB SPL while the speech signal will be adapted to find the 50% speech reception threshold (SRT).

  • BehavioralAudiologist Fitting Questionnaire

    After the fitting of Hearing Aid at inclusion, the audiologist will complete a questionnaire describing the fitting and justifying fitting decisions and will collect the demographic information

  • BehavioralPatient Satisfaction Questionnaire

    The patient will be giving a Patient satisfaction Questionnaire, with questions regarding device and accessory use. The audiologist will go over the instructions for filling out the questionnaire at inclusion. Patients will be asked to complete the questionnaire and return it at the next visit, 6 months after inclusion.

  • BehavioralAutoSens Feedback Discussion Form

    6 months after inclusion and fitting, the audiologist discusses the use of AS clinic with the subject and completes the AS questionnaire (questionnaire on the experience of using the processor in different listening situations).

06

What researchers measure

Primary outcomes

  1. Speech in noise perception (FraSimat)

    Difference in the FraSimat score obtained with the Sky HS programmed in Omni versus the score obtained in AS Target. The scores vary from -15,0 to +15,0, the higher the score is, better is the patient's hearing comprehension.

    Time frame: 6 months

Secondary outcomes

  1. Speech in noise perception (FraSimat)

    Difference in the FraSimat score obtained with the Sky HS programmed in AS Clinic versus the score obtained in Omni. The scores vary from -15,0 to +15,0, the higher the score is, better is the patient's hearing comprehension.

    Time frame: 6 months

  2. Speech in noise perception (FraSimat)

    Difference in the FraSimat score obtained with the Sky HS programmed in AS Clinic versus the score obtained in AS Target. The scores vary from -15,0 to +15,0, the higher the score is, better is the patient's hearing comprehension.

    Time frame: 6 months

  3. Patient satisfaction - device

    A patient questionnaire will be used to determine patient satisfaction with the devices. The scores vary from 0 to 10, the higher the score is better is the patient's satisfaction.

    Time frame: 6 months

  4. Patient satisfaction -listening

    With the help of the audiologist, patients will discuss and rate listening quality in different listening situations. The scores vary from 1 to 5, the higher the score is better is the patient's listening quality.

    Time frame: 6 months

  5. Audiologist programming modifications

    An audiologist questionnaire will be used to determine the programming modifications and decisions made by the audiologist for each individual patient. The questionnaire doesn't involve any scoring.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Audiophonology Unit of the Ear, Nose and Throat (ENT) Department ("Oto-rhino-laryngologie (ORL) et chirurgie cervico-faciale") at the Necker-Enfants Malades hospital (AP-HP).
    Paris, 75015, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 197 non-industry interventional studies with no phase under Hearing Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 59. This study's planned 24 months is below that.

Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 6, 2024
StartActual
Dec 11, 2024
Primary completionEst.
Dec 11, 2026
CompletionEst.
Jun 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06400992
Collaborators
Advanced Bionics AG, URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
May 6, 2024
Start date
Dec 11, 2024
Primary completion
Dec 11, 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 3, 2026

Study contacts

Nathalie LOUNDON, MD, PhD
Contact
natalie.loundon@aphp.fr
01 71 39 67 82 ext. +33
Gael PLASTOW
Contact
gael.plastow@aphp.fr
0144381711 ext. +33
Nathalie LOUNDON, MD,PhD
study director · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion